Latest filing published 23 Oct 2026 for 티움바이오.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by 김훈택 on record concern 티움바이오, in the capacity of chief executive. Between 4 June 2021 and 23 October 2026, the trades on record add up to 21 filings.
The open-market side counts 6 purchases alongside 2 sales. No amount is published for 8 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2026: 1 purchase and 1 sale on the market.
The newest entry dates from 23 October 2026: a transaction, in 티움바이오. The clock since the last published purchase (24 June 2026) now reads 123 days. Typically, a trade is published a median of 3 days after it takes place. This delay matters because a trade only becomes useful information once it is public. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations